VLA Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.45 |
| 52 Week High | €7.85 |
| 52 Week Low | €2.95 |
| Beta | 0.83 |
| 1 Month Change | -4.78% |
| 3 Month Change | -9.15% |
| 1 Year Change | -21.04% |
| 3 Year Change | -73.08% |
| 5 Year Change | 0.61% |
| Change since IPO | -68.56% |
Recent News & Updates
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05
Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15Recent updates
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Is Valneva (EPA:VLA) Using Debt Sensibly?
Sep 18Industry Analysts Just Upgraded Their Valneva SE (EPA:VLA) Revenue Forecasts By 55%
Aug 13Party Time: Brokers Just Made Major Increases To Their Valneva SE (EPA:VLA) Earnings Forecasts
Jul 28Shareholder Returns
| VLA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.9% | -0.06% | -0.2% |
| 1Y | -21.0% | -4.3% | 2.4% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned -8.2% over the past year.
Return vs Market: VLA underperformed the French Market which returned 4% over the past year.
Price Volatility
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VLA has not had significant price volatility in the past 3 months.
Volatility Over Time: VLA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 676 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLA fundamental statistics | |
|---|---|
| Market cap | €478.26m |
| Earnings (TTM) | -€101.43m |
| Revenue (TTM) | €153.71m |
3.1x
P/S Ratio-4.7x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLA income statement (TTM) | |
|---|---|
| Revenue | €153.71m |
| Cost of Revenue | €160.77m |
| Gross Profit | -€7.06m |
| Other Expenses | €94.37m |
| Earnings | -€101.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -4.59% |
| Net Profit Margin | -65.99% |
| Debt/Equity Ratio | 137.9% |
How did VLA perform over the long term?
See historical performance and comparison